Revenue ₹1,848 Cr (+4% YoY)
Promise tracking available after 2+ quarters of coverage.
View all executive profiles for Alembic Pharmaceuticals LimitedAlembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25...
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹1,848 Cr (+4% YoY)
Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25% (vs 24% YoY).
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
15 Jan 2026
Revenue ₹2,876 Cr (+11% YoY)
Alembic Pharmaceuticals reported Q3 FY26 revenue of ₹2,876 crore, up 11% YoY, driven by volume expansion and new launches, partially offset by US generics and API pric...
neutral
medium
Scorecard starts after historical backfill
Read full analysis →